Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss due to DHT is causing distress, with Minoxidil, finasteride, and RU58841 being potential treatments. The conversation includes humor and frustration about the topic.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

A 28 year old male experiencing diffuse thinning, chronic dandruff and scalp crust (seborrheic dermatitis), with replies discussing the use of topical fin for hormone imbalances and Nizoral for seb derm.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The user has been taking dutasteride for 9 months and is satisfied with the hair growth results. They had a hair transplant and don't want to share hairline progress.

User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

The user is experiencing significant hair shedding and suspects it may be due to low serum ferritin levels rather than worsening androgenetic alopecia. They have resumed iron supplementation and are seeking additional solutions to address the shedding.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.

The conversation discusses hair loss treatment progress over 7 months using Dutasteride, oral Minoxidil, and recently started RU58841. The last photo shows the progress made with these treatments.

The user experienced worsening hair density after using finasteride, dutasteride, and RU58841, suspecting RU58841 might be the cause. They are considering stopping RU58841 after a scalp biopsy, while others share mixed experiences with RU58841's effectiveness.

The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

The user shared progress on hair restoration using dutasteride, oral minoxidil, and 2800 grafts, noting significant improvement in hair thickness and coverage. They discussed the importance of continuing DHT blockers like finasteride or dutasteride post-transplant to prevent further hair thinning.

The user experienced side effects from various hair loss treatments, including RU58841, finasteride, and dutasteride. They are uncertain about what treatment to try next.

The user switched from finasteride to dutasteride for hair loss treatment and is experiencing shedding after 4 months. Another person suggests that this is not unusual and recommends giving it more time.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user is experiencing rapid hair loss despite using dutasteride, finasteride, and minoxidil, and is concerned about high estradiol and testosterone levels. They are advised to consult an endocrinologist for potential hormonal imbalances.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.